Ehlers-Danlos Syndrome, Hypermobility Mega Study
Contents
Ehlers-Danlos Syndrome, Hypermobility
Ehlers-Danlos Syndrome, Hypermobility

Related

A
1 to 5 Rating
A
Symptoms
A
Factors
A
Effects

Tags

Ehlers-Danlos Syndrome
Ehlers-Danlos Syndrome, Hypermobility

Causes of Ehlers-Danlos Syndrome, Hypermobility

User reported causes of Ehlers-Danlos Syndrome, Hypermobility based on their intuition.

Cause Agree
Genetics 97%
Stress to Joints (I.e. Heavy Lifting) 80%
Standing for Extended Periods of Time 75%
Frail Cartilage 50%
Became Deconditioned (Lots of Rest Due to Another Problem) 46%

Treatments

User-reported effectiveness in treating Ehlers-Danlos Syndrome, Hypermobility

Treatment Major Improvement Moderate Improvement Much Worse No Effect Worse Responses
Pilates 4% 40% 12% 36% 8% 25
Massage 16% 48% 5% 16% 15% 62
Physical Therapy 17% 26% 11% 32% 14% 72
Ibuprofen 8% 46% 0% 42% 3% 59
TENS 0% 50% 15% 35% 0% 40
Acupuncture 5% 26% 3% 55% 11% 38
Yoga 8% 25% 10% 33% 25% 40
Ice 4% 47% 11% 24% 13% 70
Heat 11% 64% 0% 21% 4% 80
Naproxen 5% 38% 8% 46% 3% 39
Glucosamine 0% 14% 11% 69% 6% 35
Tramadol 5% 35% 10% 25% 25% 20
Magnesium 10% 20% 0% 68% 2% 41
Vitamin D 2% 34% 2% 61% 2% 56
Vitamin C 9% 17% 2% 72% 0% 46
Vicodin (Hydrocodone) 22% 44% 11% 17% 6% 18
MSM 7% 14% 0% 79% 0% 14
Fentanyl Patch 33% 0% 0% 67% 0% 3
Calcium 2% 10% 4% 84% 0% 50
Midodrine 60% 20% 0% 20% 0% 5
Savella 25% 0% 25% 25% 25% 4
Voltaren Gel 8% 31% 15% 46% 0% 13
Excedrin Migraine 4% 54% 4% 38% 0% 26
Florinef 0% 50% 50% 0% 0% 2
Chiropractic Adjustment 8% 30% 18% 30% 15% 40
ACDF (Anterior Cervical Discectomy & Fusion) 75% 25% 0% 0% 0% 4
Lumbar Laminectomy/decompression 50% 33% 17% 0% 0% 6
Mobic/Movalis/Melox/Recoxa (Meloxicam) 24% 35% 6% 35% 0% 17
Spine Rehabilitation/ Pain Management 21% 36% 7% 32% 4% 28
Posterior Lumbar Interbody Fusion (PLIF) 25% 50% 0% 25% 0% 4
Radiofrequency Ablaition 100% 0% 0% 0% 0% 1
Hyaluronic Acid (Hyaluronan) 0% 50% 0% 50% 0% 6
Oramorph 0% 100% 0% 0% 0% 1
Muscle Relaxors 10% 30% 20% 40% 0% 10
Neurontin/Gabapentin 33% 0% 17% 17% 33% 6
Fascet Injections 33% 0% 33% 0% 33% 3
SI Injections 33% 0% 67% 0% 0% 3
Chondroitin/Chondroitin Sulfate 0% 8% 8% 76% 8% 25

Below is the degree of change seen after Ehlers-Danlos Syndrome, Hypermobility is higher than average.

Below is the change in Ehlers-Danlos Syndrome, Hypermobility seen after the predictor is higher than average.

Outcomes
of
Below is the change in the listed outcome after is higher than average.
Sort by Effect Size
Sort by Confidence
% Change from Baseline*
*
Change in the listed outcome after is higher than average.
Predictors
of
Below is the change in after the listed predictor is higher than average.
Sort by Effect Size
Sort by Confidence
% Change from Baseline*
*
Change from the average seen after the predictor is higher than average.

Ehlers-Danlos Syndrome, Hypermobility Info

Property Value
Variable Name Ehlers-Danlos Syndrome, Hypermobility
Aggregation Method MEAN
Analysis Performed At 2020-03-02
Duration of Action 24 hours
Maximum Allowed Value 5 out of 5
Minimum Allowed Value 1 out of 5
Number of Aggregate Predictors 0
Number of Aggregate Outcomes 0
Number of Measurements 0
Number of Measurements (including those generated by tagged, joined, or child variables) 0
Public true
Onset Delay 0 seconds
Unit 1 to 5 Rating
User Variables 0
Variable Category Symptoms
Variable ID 86820